Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced the completion of enrollment for its Explore-CKD Phase 2 trial. The ...

Court of Protection decides whether continued life-sustaining treatment is in the best interests of a patient in a prolonged ...

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic.

Researchers at the Smidt Heart Institute at Cedars-Sinai have found that women with type 2 diabetes who are diagnosed with ...

Primary aldosteronism treatment response was associated with higher plasma renin activity and serum potassium levels and lower aldosterone.